US OptionsDetailed Quotes
ADVM240719C7000
- 1.00
- -2.10-67.74%
15min DelayClose Jul 19 15:59 ET
1.40High1.00Low
1.40Open3.10Pre Close13 Volume919 Open Interest7.00Strike Price1.71KTurnover0.00%IV-2.08%PremiumJul 19, 2024Expiry Date1.17Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.17Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Adverum Biotechnologies Stock Discussion
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
$EyePoint Pharmaceuticals(EYPT.US)$
$Adverum Biotechnologies(ADVM.US)$
$Regenxbio(RGNX.US)$
$4D Molecular Therapeutics(FDMT.US)$
$Kodiak Sciences(KOD.US)$
No comment yet